Nabriva Therapeutics Gets FDA Green Light for Pneumonia Antibiotic
The US FDA has approved Nabriva Therapeutics’ Xenleta for treating community-acquired bacterial pneumonia, the first…
The US FDA has approved Nabriva Therapeutics’ Xenleta for treating community-acquired bacterial pneumonia, the first…
Nabriva Therapeutics has obtained positive Phase III results for its antibiotic lefamulin and plans to…
This week marks the WHO's World Antibiotic Awareness Week. We had a look at some of…
The novel antibiotic lefamulin brought home late-stage success to Nabriva by proving itself to be on…
We interviewed David Chiswell, a pioneer in the development of therapeutic antibodies and now the…
We had a look into European biotech and created a map with the biggest biotech…
Classical music, the Danube, Schnitzel, and apple strüdel - a typical combination of Vienna. The…
Monday: Nabriva Therapeutics launched its $100M IPO on the NASDAQ to develop new antibiotics Tuesday: the Francis…